Featured Research

from universities, journals, and other organizations

New fusion gene plays role in some stomach cancers

Date:
April 7, 2011
Source:
Duke University Medical Center
Summary:
A newly discovered hybrid gene appears to play a direct role in some stomach cancers. The hybrid gene is a fusion of two separate genes, and is one of the first described in gastric cancer, which is the most lethal malignancy worldwide after lung cancer.

A newly discovered hybrid gene appears to play a direct role in some stomach cancers, according to an international team of scientists led by researchers at Duke-NUS Graduate Medical School Singapore.

The hybrid gene is a fusion of two separate genes, and is one of the first described in gastric cancer, which is the most lethal malignancy worldwide after lung cancer. The disease kills an estimated 740,000 people a year, including nearly 11,000 annually in the United States.

The gene discovery may one day give doctors a more effective way to use current therapies, plus help researchers develop new drugs and diagnostic tools for gastric cancer.

"This is an extremely exciting area, as it opens up a potential role for fusion genes in solid cancer diagnostics and treatment, similar to the fundamental role they have played in the blood cancers," said Dr. Patrick Tan, associate professor in the Cancer and Stem Cell Biology Program at the Duke-NUS Graduate Medical School Singapore. Tan was principal investigator of the study published in the April 6, 2011, issue of the journal Science Translational Medicine.

Tan said the research team -- which also included scientists from the National University of Singapore, National Cancer Centre of Singapore, the Genome Institute of Singapore, Yonsei University College of Medicine in Seoul, South Korea, and Howard University -- used a novel genomic approach to isolate the fusion gene.

The technology is called genomic breakpoint analysis (GBA), which has been used to identify fusion genes in leukemia, but has had less success in pinpointing them in complex solid tumors.

By using the technology to home in on abnormal genes in 133 stomach cancer tumors and cell lines, the Singapore-based research group found evidence of a single genetic error that was common to four of the cancer samples.

Finding the error led the scientists to the CD44-SLC1A2 fusion gene, which resulted when two nearby genes blended into one. The SLC1A2 gene is associated with the metabolism of the amino acid glutamate, which can work like a fertilizer encouraging tumor growth and survival, while the CD44 gene serves as a sort of "on" switch.

Melded into one, the CD44-SLC1A2 hybrid appears to fuel stomach tumors. Tan's team estimates the fusion gene may be at work in up to 2 percent of stomach cancers.

"Using high-throughput genomic technologies such as sequencing and GBA, we are now finding that cancers do express many fusion genes," Tan said. "The current feeling is that while most of these are harmless and 'noise' from genomic instability, there can be cases, such as CD44-SLC1A2, where the fusion gene contributes actively to the cancer."

The finding could lead to improved therapies for this subset of stomach cancers. As part of the study, the researchers used a gene silencing approach to reduce the levels of CD44-SLC1A2 in cancer cell lines. They found that this caused a reduction in the glutamate levels of cancer cells, and made the cells more vulnerable to the effects of cisplatin, a common chemotherapy.

"It does suggest that drugs that inhibit SLC1A2 function could be used to sensitize tumors to chemotherapy," Tan said. "Such glutamate uptake inhibitors are available, and we are working very hard to test this possibility."

In addition to Tan, study authors included: Jiong Tao, Baohua Huang and Celestial Yap of the National University of Singapore; Nian Tao Deng, Chia Huey Ooi, Iain Beehuat Tan and Shenli Zhang of the Duke-NUS Graduate Medical School; Kalpana Ramnarayanan, Hue Kian Oh, Jeanie Wu, Minghui Lee, Siew Hong Leong and Oi Lian Kon of the National Cancer Centre of Singapore;

Seong Soo Lim, Valere Cacheux and Nallasivam Palanisamy of the Genome Institute of Singapore; Sun Young Rha and Hyun Cheol Chung of the Yonsei University College of Medicine; Duane T. Smoot and Hassan Ashktorab of Howard University College of Medicine.

The study was funded by the Biomedical Research Council and National Medical Research Council of Singapore, Duke-NUS Graduate Medical School Singapore, and the Cancer Sciences Institute of Singapore.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jiong Tao et al. CD44-SLC1A2 Gene Fusions in Gastric Cancer. Sci Transl Med, 6 April 2011: Vol. 3, Issue 77, p. 77ra30 DOI: 10.1126/scitranslmed.3001423

Cite This Page:

Duke University Medical Center. "New fusion gene plays role in some stomach cancers." ScienceDaily. ScienceDaily, 7 April 2011. <www.sciencedaily.com/releases/2011/04/110406142343.htm>.
Duke University Medical Center. (2011, April 7). New fusion gene plays role in some stomach cancers. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/04/110406142343.htm
Duke University Medical Center. "New fusion gene plays role in some stomach cancers." ScienceDaily. www.sciencedaily.com/releases/2011/04/110406142343.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins